Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07452406 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients

Study acronym: PRO-WEAN HFNC
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 30 days later Mar 31, 2028 → Apr 30, 2028
See other at-risk trials from Rush University Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Sep 1, 2026 to Nov 1, 2026
    • Primary completion pushed from Mar 31, 2028 to Apr 30, 2028
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 17 entries
  2. Primary completion pushed from Mar 31, 2027 to Mar 31, 2028
    • Start date: Jun 1, 2026 to Sep 1, 2026
    • Study completion pushed from Apr 28, 2027 to Jun 28, 2028
    • Collaborators: 7 to 6
    v3
  3. Interventions: Protocolized HFNC Weaning Strategy (Other), Usual Care HFNC Weaning (Other) to Protocolized HFNC Weaning Strategy (Behavioral), Usual Care HFNC Weaning (Behavioral)
    • Study title shortened, about 5 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
High-flow nasal cannula (HFNC) is a type of oxygen therapy commonly used in adults with breathing problems. While HFNC can help patients avoid breathing tubes and improve oxygen levels, there is no standard method for deciding how and when to reduce and stop this therapy once a patient improves. In many hospitals, these decisions vary from clinician to clinician. This study will compare usual care with a standardized step-by-step plan for reducing HFNC support. Eight hospitals will participate and will switch from usual care to the standardized plan at different time points during the study. The main goal is to determine whether the standardized weaning plan increases the number of patients who can successfully stop HFNC within 5 days. The study will also evaluate how long patients remain on HFNC, whether they need additional breathing support, and how long they stay in the hospital. The results may help develop clearer guidance for safely and efficiently stopping HFNC therapy.
Trial Details
NCT Number NCT07452406
Lead Sponsor Rush University Medical Center
Collaborators: The First Affiliated Hospital of Xiamen University, First Hospital of China Medical University, Shanghai Zhongshan Hospital, Binzhou Medical University, First Affiliated Hospital of Chongqing Medical University, Changhai Hospital
Conditions
(from sponsor)		 Acute Hypoxemic Respiratory Failure, High-Flow Nasal Cannula Therapy
Related terms Respiratory Insufficiency
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov